

AMENDMENTS TO THE SPECIFICATION

Page 1, line 4, please amend the paragraph as follows:

This application is a U.S. National Phase Application pursuant to 35 U.S.C. 371 of International Application No. PCT/GB2003/003966, filed on September 12, 2003, claiming benefit of priority of claims priority to U.S. Provisional Application provisional application Serial No. 60/413,685, filed on September 26, 2002, and U.S. Provisional Application provisional application Serial No. 60/417,688, filed on October 10, 2002, the disclosures of which are incorporated by reference in their entirety. Certain of the studies described herein were performed with the aid of federal support using the following grants from the National Institutes of Health: HL68033; GM47522; HL49234 and HL64013.

Page 38, immediately after claim 21, please insert a new page containing the following abstract of the application:

--

ABSTRACT

The present invention provides anti-angiogenic derived from pigment epithelium-derived factor(PEDF) pharmaceutical compositions comprising the peptides, and methods of preventing angiogenesis. Such methods are useful in treating angiogenesis-associated disorders and diseases.--